DS
DNA icon

David Shaw’s Ginkgo Bioworks DNA Stock Holding History

David Shaw’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-73,400
Closed -$598K – 4492
2024
Q3 		$598K Buy
+73,400
New +$735K ﹤0.01% 3593

Other funds holding DNA

California State Teachers Retirement System (CalSTRS)
California State Teachers Retirement System (CalSTRS) West Sacramento, California $782B AUM 28.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

David Shaw's DNA Position: Q2 2026 in Review

David Shaw increased its Ginkgo Bioworks (DNA) stake by 457% in Q2 2026, buying an estimated $1.04M and bringing the position to 151,356 shares worth $1.5M. The position accounts for ﹤0.01% of the portfolio, ranked #3443.

David Shaw first reported a position in DNA in Q3 2021 and has held it in 16 quarters since. The position peaked at $10.4M in Q3 2021. 184 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • David Shaw held 151,356 shares of Ginkgo Bioworks worth $1.5M as of Q2 2026.
  • David Shaw bought 124,187 Ginkgo Bioworks shares in Q2 2026, an estimated $1.04M.
  • Ginkgo Bioworks made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #3443 holding.
  • David Shaw first reported a position in Ginkgo Bioworks in Q3 2021 and has held it in 16 quarters since.
  • David Shaw's Ginkgo Bioworks position peaked at $10.4M in Q3 2021.
  • 184 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.